ClinicalTrials.gg
AvailableNCT01277796HECTUpdated Jan 17, 2011

Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis

An expanded access record providing Heat pack conduction-heat therapy in Cutaneous Leishmaniasis, sponsored by Universidad Peruana Cayetano Heredia. Available. Open to participants aged 8 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-01-17.

Sponsored by Universidad Peruana Cayetano Heredia · Expanded access

Study type
Expanded access
Ages
8 Years to 80 Years
Sex
All
01

Study summary

Current standard therapies with chemotherapy (CT) for Cutaneous Leishmaniasis (CL) are expensive, toxic/allergenic, frequently ineffective, burdensome, and often unavailable. Thermotherapy is a clinically validated first line alternative for the treatment of Cutaneous Leishmaniasis in South America. However, current heat-delivery modalities are either too costly or lack governmental approval required to be made widely available to endemic areas. The investigators have adapted a reliable, safe, and low-cost heat pack for Cutaneous Leishmaniasis that the investigators have named the HECT-CL device. In this pilot study the investigators will enroll 25 patients who have either failed or are not candidates for pentivalent antimonies. The hypothesis states that the HECT-CL device demonstrates efficacy non-statistically inferior to estimates for current South American Pentavalent Antimonial cure rates (76%) while demonstrating basic safety and tolerability.

02

Conditions studied

  • Cutaneous Leishmaniasis
03

In context

Leishmaniasis, Cutaneous

103 studies on the registry are indexed under Leishmaniasis, Cutaneous; 18 are open to participants now.

Browse Leishmaniasis, Cutaneous studies →

Lead sponsor

Universidad Peruana Cayetano Heredia is the lead sponsor of 49 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 80 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • with CL diagnosed by skin smear (WHO method), , culture, PCR
  • aged 8-80 years old
  • with no more than 3 lesions
  • ulcerative and non-ulcerative ulcers less than 4 cm diameter.
  • allergy, prohibitive side effects to standard chemotherapy, or other to antimonial treatment (e.g. cardiac arrhythmia)
  • capable of signing an or having capable guardians (in the case of minors).
  • Children ≥ 8 years of age must give written or verbal informed assent along with written consent of their guardians.

Exclusion criteria

Exclusion Criteria:

  • lesions less than 2cm from the nose, mouth, ears, or eyes.
  • clinically diagnosed with mucosal involvement.
  • evidence of lymph node involvement on exam.
  • unable or unwilling to commit to the treatment and follow-up plan.
  • prior CL treatment within last 1 month.
  • pregnant or lactating
  • uncontrolled severe systemic illness or state.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Access details

Study type
Expanded access

Available treatment

  • DeviceHeat pack conduction-heat therapy

    Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01277796
Lead sponsor
Universidad Peruana Cayetano Heredia
Collaborators
Tulane University School of Medicine
First posted
Jan 17, 2011
Last update
Jan 17, 2011

Study contacts

Alejandro Llanos-Cuentas, MD, PhD
Contact
elmer.llanos@upch.pe
51-1-482-7739
Alejandro Llanos-Cuentas, MD, PhD
principal investigator · Universidad Peruana Cayetano Heredia
Witzig Richard, MD, MPH
principal investigator · Tulane Medical School
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion